BURLINGTON, Mass., Sept. 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the European market for surgical hemostats, internal tissue sealants and adhesion barriers will grow moderately through 2022. This market is highly dynamic due to the converging impact of several positive and negative revenue growth factors, given the variety of products covered.
Other key findings from Decision Resources Group's coverage of the European surgical hemostat, internal tissue sealant and adhesion barrier market:
- Underpenetrated market: Compared to the United States, the European market for surgical hemostats, internal tissue sealants and adhesion barriers is underpenetrated. Therefore, manufacturer marketing and accumulation of clinical evidence will be the key drivers of growth. The aging population and thus rising number of surgical procedures will also positively influence market expansion.
- Clinical trials: Results from clinical trials are particularly important in the internal tissue sealant market because of the complexity of these procedures. Because they are required to hold together two tissue surfaces rather than to clot blood or act as a barrier, they can inherently lead to a greater number of complications.
- Austerity measures: Austerity measures, especially in France, Spain, Italy and the United Kingdom, have caused some physicians to revert back to less costly traditional methods to control bleeding, such as sutures or cautery. Adhesion barriers, which are not strictly necessary, are also limited by the prevalence of cost-consciousness in most of Europe.
Comments from Decision Resources Group Analyst Senior Analyst Rene Azeez:
- "The trend toward minimally invasive procedures will limit market potential because these procedures use smaller incisions and therefore often do not require additional support to control bleeding or prevent the development of adhesions. Furthermore, the placement of surgical hemostats, internal tissue sealants and adhesion barriers in these situations is complex."
- "Multifunctional products such as Baxter's TISSEEL that can compete with surgical hemostats, internal tissue sealants and adhesion barriers have gained interest in Europe. In fact, in Italy this product is used in multiple indications off-label, which makes it difficult for other products to gain adoption."
- Rene Azeez has written a Medtech 360 report on this subject entitled European Markets for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers 2014.
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group